BPC-157 Gut Health: What Rat and Human Studies Show
What Do Studies Show About BPC-157 for Gut Health?
BPC-157 gut health research is mostly rat work, plus two small human studies. Both human studies gave it as an enema, a liquid passed into the rectum. Both were reported only as meeting abstracts, which are short conference summaries. The FDA found "a lack of evidence" that it works for ulcerative colitis.
BPC-157 is a chain of 15 amino acids. Amino acids are the building blocks of protein. It comes from a larger protein found in human gastric juice, the fluid in the stomach (Chang 2011). A research group in Zagreb, Croatia, first described it. The group calls it native to human gastric juice (Sikiric 2018).
That group's reviews describe two effects in their animal work. The first is that it guards the endothelium. That is the layer of cells that lines blood vessels. The second is that it draws in blood vessels. After an injury makes a hole in the stomach, they report that BPC-157 activates nearby vessels "running" toward it (Sikiric 2018). They report the same kind of effect in rats after the colon's blood supply was cut off and then restored (Sikiric 2020). This is called ischaemia-reperfusion colitis, damage to the colon from lost blood flow. They also report it in duodenal lesions after a vein was tied off, and after a hole was made in the caecum. The duodenum is the first part of the small bowel. The caecum is the pouch where the large bowel starts.
What does it do to inflammation?
The same 2020 review says BPC-157 countered rises in IL-6 and TNF-alpha. These are cytokines, the signal proteins the immune system uses to drive swelling. That finding was in tumour cachexia, the muscle wasting seen with cancer. The review does not report it in a gut disease.
Is there a gut-brain angle?
A 2023 review by the Zagreb group proposes one. Its title says BPC-157 "may recover brain-gut axis and gut-brain axis function" (Sikiric 2023). The gut-brain axis is the two-way link between the gut and the brain. The review bases this on the group's animal work on behaviour, muscle, the heart, blood vessels and organ damage. An older review by the same group says BPC-157 given peripherally, meaning outside the brain, induced serotonin release in the substantia nigra (Sikiric 2006). The substantia nigra is a part of the brain. For the wider picture, see our BPC-157 complete guide. Our page on BPC-157 testosterone cypionate covers the pairing with testosterone.
Does BPC-157 Help With Gut Health in Human Trials?
No published human trial has shown that it does. In 2026 the FDA wrote a briefing document on BPC-157 for its advisers. It lists five human studies. Two were gut studies. Both gave it as an enema, and both had a placebo group. A placebo is a dummy treatment. Both were reported only as meeting abstracts.
| Study | Who | BPC-157 Dose | What Came Out |
|---|---|---|---|
| Veljaca 2002 and 2003 (meeting abstracts) | 32 healthy volunteers: 24 given BPC-157, 8 a placebo | Enema of 0.25, 0.5, 1 or 2 mg per kg. One dose, a week off, then once daily for 7 days. | The authors reported no significant adverse events linked to treatment. Blood levels of BPC-157 were mostly too low to measure. |
| Ruenzi 2005 (meeting abstract) | 53 people with mild to moderate ulcerative colitis; 46 finished | Enema of 80 mg or placebo, once daily for 2 weeks | The FDA found "a lack of evidence to make a conclusion on the effectiveness of BPC-157 for treating UC." |
Of the ulcerative colitis study (Ruenzi 2005), the FDA said "interpretation of the results is limited." It named two causes: "the lack of details provided in the meeting abstract and the exploratory nature of the study." The FDA found only meeting abstracts for both studies.
What did the 2006 review report?
A 2006 review names three codes in its title. They are PL-10, PLD-116 and PL 14736, from the drug firm Pliva in Croatia. The review says BPC-157 was "safe in clinical trials for inflammatory bowel disease" (Sikiric 2006). Its abstract gives no trial results.
The lesion results in that review come from rats. The rats got alcohol into a full, stretched stomach. BPC-157 cut down lesions of the stomach, gullet and duodenum. The authors report that the standard drugs atropine, ranitidine and omeprazole had only a partial effect. They tie this to blood vessels near the stomach staying intact.
What did the 2026 review conclude?
It named the gap outright. A 2026 review found more than 30 years of animal and lab work with consistent effects (Mateescu 2026). It also found no approved formulation and no validated dosing regimen. And it found no completed Phase II clinical trial. A Phase II trial tests whether a drug works in patients. It counted fewer than 30 people across three small pilot studies, none with a control group.
Is BPC-157 Good for Gut Health With Crohn's or Ulcerative Colitis?
No human study shows that it is, for either disease. In the FDA's list, ulcerative colitis (UC) is the only gut disease with a human BPC-157 study. That was the Ruenzi enema study above. The FDA found a lack of evidence on whether it works. The FDA's list has no human study in Crohn's disease.
What do the rat studies show?
The rat work looks at gut wounds, not at either disease as it occurs in people. In one study, rats had a fistula from the colon to the skin. A fistula is an odd tunnel between two body parts. BPC-157 helped the fistula close (Klicek 2008). It worked in drinking water or as a shot into the belly. In the same study, sulphasalazine, a standard colitis drug, was only moderately effective. A corticosteroid made healing worse.
In another study, rats had two cut ends of the small bowel joined by surgery. Surgeons call this join an anastomosis. BPC-157 shots into the belly helped the join heal (Vuksic 2007). A 2020 review by the same group covers fistulas and joins all along the rat gut (Sikiric 2020). It says the effect held when NSAIDs or colitis also harmed the joins.
What Do Studies Say About BPC-157 Gut Health Benefits for Leaky Gut?
No human study has tested BPC-157 for leaky gut. Leaky gut means the gut lining lets through more than it should. A 2020 review says NSAIDs, stress, bile acids and alcohol can cause it. NSAIDs are common painkillers such as ibuprofen and diclofenac. The review sets out how BPC-157 might help against leaky gut after NSAIDs (Park 2020). It says this is the first time anyone has described it.
What do the NSAID studies show?
One rat study used diclofenac, a widely used NSAID. Diclofenac caused severe stomach, bowel and liver lesions, and brain swelling. The authors report that BPC-157 strongly countered this (Ilic 2011). It worked as a shot into the belly or in drinking water. The study's abstract reports no measure of how leaky the gut was.
The Zagreb group also says BPC-157 counters harm to the lining of the stomach's blood vessels. In their account, that harm comes first and then leads to damage of the stomach's surface cells. This is the group's own summary, in its 2020 review in Gut and Liver.
How Do BPC-157 and TB-500 for Gut Health Compare?
Neither has shown a gut benefit in people. The table sets out what the sources say about each.
| Question | BPC-157 | TB-500 |
|---|---|---|
| What it is | A chain of 15 amino acids | A fragment of amino acids 17 to 23 of thymosin beta-4, plus an acetyl group, per the FDA TB-500 briefing |
| Human gut studies | Two enema studies, meeting abstracts only | None. The FDA found no clinical studies or human exposure data by any route. |
| Animal gut studies | Rat studies of ulcers, fistulas, joins and NSAID damage | None found in a PubMed search we ran |
| FDA view on effectiveness | "a lack of evidence" for UC | "a lack of evidence to evaluate the effectiveness" for wound healing, the only use the FDA reviewed; the FDA did not review a gut use |
The FDA also says thymosin beta-4 and TB-500 are not the same substance. So a study of one does not tell you about the other. Readers often ask about pairing BPC-157 with KPV. We cover that in our KPV and BPC-157 gut stack guide.
What Is Known About Oral BPC-157 for Gut Health?
In people, very little. The FDA found no human data on how BPC-157 is taken up after a dose by mouth. One trial planned to give it as tablets of 1 mg (NCT02637284). Its status is unknown, and it has posted no results.
In rats, doses by mouth were tested. The diclofenac and fistula studies gave it in drinking water or as a shot into the belly. The authors report that both routes worked (Ilic 2011; Klicek 2008). The Zagreb group says it stays stable in human gastric juice for more than 24 hours (Sikiric 2020).
Bioavailability is the share of a dose that reaches the blood. One study gave BPC-157 as a shot into a muscle (He 2022). The share was 14 to 19 percent in rats. In beagle dogs it was 45 to 51 percent. No study has measured it in people. We set out the routes in our oral versus injectable comparison.
What BPC-157 Dosage for Gut Health Do Studies Use?
No study has set a BPC-157 dosage for gut health in people. The 2026 review by Mateescu and colleagues found no validated dosing regimen. The table lists the doses that gut studies used, in each source's own terms.
| Source | Who | Route | Dose and Length |
|---|---|---|---|
| Veljaca 2002 and 2003, per the FDA briefing | Healthy volunteers | Enema | 0.25, 0.5, 1 or 2 mg per kg; one dose, a week off, then once daily for 7 days |
| Ruenzi 2005, per the FDA briefing | People with ulcerative colitis | Enema | 80 mg once daily for 2 weeks |
| Ilic 2011 | Rats given diclofenac | Into the belly, or drinking water | 10 mcg or 10 ng per kg; or 0.16 mcg or 0.16 ng per ml of water |
| Klicek 2008 | Rats with a colon fistula | Drinking water, or into the belly once daily | 10 mcg or 10 ng per kg, up to 28 days |
A nanogram (ng) is one thousandth of a microgram (mcg). The healthy-volunteer study gave eight enema doses in all, and the ulcerative colitis study gave daily enemas for 2 weeks. The FDA describes the doses in these studies as "likely exploratory in nature."
The peptide clears fast in animals. Its half-life was under 30 minutes in rats and dogs (He 2022). Half-life is the time it takes for half of a dose to leave the blood. The 2026 review says blood levels rose in line with the dose (Mateescu 2026). For people, the FDA says "there is no information to assess the pharmacokinetics of BPC-157 in humans." Pharmacokinetics is how the body takes up and clears a drug. Our BPC-157 dosing guide lists each dose a named study used.
What Is Known About the Safety of a BPC-157 Protocol for Gut Health?
No study has tested the safety of a BPC-157 protocol for gut health. In the enema study in healthy people, headache and wind were most common. They showed no clear gap from placebo, per the FDA briefing. Across the five human studies, the FDA wrote: "No serious adverse events appear to have been reported." Even so, it found "insufficient clinical safety information to characterize the safety profile."
A 2025 pilot gave BPC-157 by drip into a vein. Two adults got 10 mg on day 1 and 20 mg on day 2. Both had had it by drip before. Neither reported side effects. Tests of the heart, liver, kidneys, thyroid and blood sugar showed no measurable effects (Lee 2025).
What did the animal toxicity work find?
It tested mice, rats, rabbits and dogs (Xu 2020). A single dose caused no effects linked to the peptide. In dogs dosed over and over, creatinine fell at 2 mg per kg but not at lower doses. Creatinine is a blood marker of kidney function. The dogs recovered within 2 weeks of stopping. Irritation where it was given was mild. It showed no genetic or embryo-fetal toxicity, meaning no harm to genes or unborn young. The Zagreb group writes that a lethal dose was not reached (Vuksic 2007).
A 2025 review notes that the FDA has not approved BPC-157 for use in medicine (Jozwiak 2025). We keep a vendor-neutral overview on our sources page.
Where to buy BPC-157
If you're researching this compound, I've linked a trusted source below. It supports the channel.
See the sources that passed →Bibliography
- Sikiric et al. 2006, Inflammopharmacology, pubmed.ncbi.nlm.nih.gov/17186181
- Vuksic et al. 2007, Surgery Today, pubmed.ncbi.nlm.nih.gov/17713731
- Klicek et al. 2008, Journal of Pharmacological Sciences, pubmed.ncbi.nlm.nih.gov/18818478
- Chang et al. 2011, Journal of Applied Physiology, pubmed.ncbi.nlm.nih.gov/21030672
- Ilic et al. 2011, Life Sciences, pubmed.ncbi.nlm.nih.gov/21295044
- Sikiric et al. 2018, Current Pharmaceutical Design, pubmed.ncbi.nlm.nih.gov/29879879
- Sikiric et al. 2020, Fistulas Healing, Current Pharmaceutical Design, pubmed.ncbi.nlm.nih.gov/32329684
- Sikiric et al. 2020, Gut and Liver, pubmed.ncbi.nlm.nih.gov/31158953
- Park et al. 2020, Current Pharmaceutical Design, pubmed.ncbi.nlm.nih.gov/32445447
- Sikiric et al. 2023, Pharmaceuticals, pubmed.ncbi.nlm.nih.gov/37242459
- Xu et al. 2020, Regulatory Toxicology and Pharmacology, pubmed.ncbi.nlm.nih.gov/32334036
- He et al. 2022, Frontiers in Pharmacology, pubmed.ncbi.nlm.nih.gov/36588717
- Lee and Burgess 2025, Alternative Therapies in Health and Medicine, pubmed.ncbi.nlm.nih.gov/40131143
- Jozwiak et al. 2025, Pharmaceuticals, pubmed.ncbi.nlm.nih.gov/40005999
- Mateescu et al. 2026, Pharmaceutics, pubmed.ncbi.nlm.nih.gov/42198317
- FDA, BPC-157 briefing document, Pharmacy Compounding Advisory Committee, July 2026, fda.gov/media/193343
- FDA, TB-500 briefing document, Pharmacy Compounding Advisory Committee, July 2026, fda.gov/media/193349
- ClinicalTrials.gov, NCT02637284
This content is for educational purposes only and is not medical advice. These compounds are intended for research use. A qualified clinician can advise on any health decision.
Where to buy BPC-157
If you're researching this compound, I've linked a trusted source below. It supports the channel.
See the sources that passed →Share this article
Frequently Asked Questions
What is BPC-157 and how does it work for gut health?
Does BPC-157 help with ulcerative colitis specifically, or is evidence mostly limited to Crohn's disease and general IBD models?
What BPC-157 doses have gut studies used, and is there a validated dosing regimen?
Is BPC-157 safe, and what does the human safety data show?
What is the difference between BPC-157 and TB-500 for gut healing?
Does BPC-157 help with leaky gut or NSAID-induced intestinal permeability?
Read Next
Disclaimer: This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.